Skip to main content
Top
Published in: Gut Pathogens 1/2021

Open Access 01-12-2021 | SARS-CoV-2 | Letter to the Editor

Improved gut microbiota features after the resolution of SARS‑CoV‑2 infection

Authors: Flavio De Maio, Gianluca Ianiro, Gaetano Coppola, Francesco Santopaolo, Valeria Abbate, Delia Mercedes Bianco, Fabio Del Zompo, Giuseppe De Matteis, Massimo Leo, Antonio Nesci, Alberto Nicoletti, Maurizio Pompili, Giovanni Cammarota, Brunella Posteraro, Maurizio Sanguinetti, Antonio Gasbarrini, Francesca Romana Ponziani

Published in: Gut Pathogens | Issue 1/2021

Login to get access

Abstract

Background

The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has a tropism for the gastrointestinal tract and several studies have shown an alteration of the gut microbiota in hospitalized infected patients. However, long-term data on microbiota changes after recovery are lacking.

Methods

We enrolled 30 patients hospitalized for SARS‑CoV‑2-related pneumonia. Their gut microbiota was analyzed within 48 h from the admission and compared with (1) that of other patients admitted for suspected bacterial pneumonia (control group) (2) that obtained from the same subject 6 months after nasopharyngeal swab negativization.

Results

Gut microbiota alpha-diversity increased 6 months after the resolution of SARS-CoV-2 infection. Bacteroidetes relative abundance was higher (≈ 36.8%) in patients with SARS-CoV-2, and declined to 18.7% when SARS-CoV-2 infection resolved (p  =  0.004). Conversely, Firmicutes were prevalent (≈ 75%) in controls and in samples collected after SARS-CoV-2 infection resolution (p  =  0.001). Ruminococcaceae, Lachnospiraceae and Blautia increased after SARS-CoV-2 infection resolution, rebalancing the gut microbiota composition.

Conclusion

SARS-CoV-2 infection is associated with changes in the gut microbiome, which tend to be reversed in long-term period.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chhibber-Goel J, Gopinathan S, Sharma A. Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections? Gut Pathog. 2021;13:14.CrossRef Chhibber-Goel J, Gopinathan S, Sharma A. Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections? Gut Pathog. 2021;13:14.CrossRef
3.
go back to reference Yeoh KY, Zuo T, Lui GCY, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698–706.CrossRef Yeoh KY, Zuo T, Lui GCY, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698–706.CrossRef
4.
go back to reference Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159(3):944-955.e8.CrossRef Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159(3):944-955.e8.CrossRef
5.
go back to reference Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020;71:2669–78.CrossRef Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020;71:2669–78.CrossRef
6.
go back to reference Ponziani FR, Del Zompo F, Nesci A, Santopaolo F, Ianiro G, Pompili M, et al. Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. Aliment Pharmacol Ther. 2020;52:1060–8.PubMed Ponziani FR, Del Zompo F, Nesci A, Santopaolo F, Ianiro G, Pompili M, et al. Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. Aliment Pharmacol Ther. 2020;52:1060–8.PubMed
7.
go back to reference Ponziani FR, Nesci A, Del Zompo F, Santopaolo F, Pompili M, Gasbarrini A, et al. Correlation between liver function tests abnormalities and interleukin-6 serum levels in patients with SARS-CoV-2 infection. Gastroenterology. 2021;160:1891–3.CrossRef Ponziani FR, Nesci A, Del Zompo F, Santopaolo F, Pompili M, Gasbarrini A, et al. Correlation between liver function tests abnormalities and interleukin-6 serum levels in patients with SARS-CoV-2 infection. Gastroenterology. 2021;160:1891–3.CrossRef
8.
go back to reference Del Zompo F, De Siena M, Ianiro G, Gasbarrini A, Pompili M, Ponziani FR. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020;24:13072–88.PubMed Del Zompo F, De Siena M, Ianiro G, Gasbarrini A, Pompili M, Ponziani FR. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020;24:13072–88.PubMed
9.
go back to reference Liu X, Mao B, Gu J, Wu J, Cui S, Wang G, et al. Blautia-a new functional genus with potential probiotic properties? Gut Microbes. 2021;13:1–21.CrossRef Liu X, Mao B, Gu J, Wu J, Cui S, Wang G, et al. Blautia-a new functional genus with potential probiotic properties? Gut Microbes. 2021;13:1–21.CrossRef
Metadata
Title
Improved gut microbiota features after the resolution of SARS‑CoV‑2 infection
Authors
Flavio De Maio
Gianluca Ianiro
Gaetano Coppola
Francesco Santopaolo
Valeria Abbate
Delia Mercedes Bianco
Fabio Del Zompo
Giuseppe De Matteis
Massimo Leo
Antonio Nesci
Alberto Nicoletti
Maurizio Pompili
Giovanni Cammarota
Brunella Posteraro
Maurizio Sanguinetti
Antonio Gasbarrini
Francesca Romana Ponziani
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2021
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-021-00459-9

Other articles of this Issue 1/2021

Gut Pathogens 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.